Phosphagenics began as an investment company, which was listed on the Australian Securities Exchange (ASX) in 1993, called Greenchip Development Capital Limited. In 2004, the company refocused its attention to the biotechnology sector and changed its name to Phosphagenics Limited.

In the early-2000s, Phosphagenics discovered a drug delivery system based on Vitamin E (tocopheryl phosphate mixture), naming it TPM®, and conducted early stage proof of concept work with global key opinion leaders on Vitamin E to characterize the basic science behind the technology.

In the mid-2000s, Phosphagenics made considerable strides in understanding and optimizing the delivery technology, and using it to formulate pharmaceutical, consumer, and animal health products. During this period, we conducted early-stage clinical trials on insulin, morphine, diclofenac, and lidocaine.

In 2009, Phosphagenics conducted its first clinical study on the TPM®/Oxycodone patch, and as the program progressed, announced that it was the first company in the world to successfully deliver oxycodone into the systemic circulation by way of a transdermal product.

In 2011, Phosphagenics launched its BioElixia® range of personal care products, which was built on a unique point of differentiation – the capacity of TPM® Dermal Delivery Technology to enhance the delivery, and thus the efficacy, of key cosmetics ingredients. Since then, the products have been launched in various global markets, including Australia, Asia and the US, as well as in various markets under licensing, bulk supply, and private label arrangements with strategic partners including GNC, Le Métier de Beaute, and Korean Drug Company.

In 2012, Phosphagenics licensed an antibiotic injectable product formulated with TPM® to Mylan for global marketing. It was also the year Phosphagenics’ first animal health products were launched by strategic partner Equine Nutrition Australia in Australia and New Zealand. Phosphagenics has since expanded its range of animal health products from horse supplements to also include horse feeds and ruminant feeds marketed through partners Equine Ergogenics Australia, Mastitis Management Australia and Integrated Animal Health.

In 2013, Phosphagenics conducted its first clinical study on the TPM®/Oxymorphone patch, and as the program progressed, announced that it was the first company in the world to deliver therapeutic levels of oxymorphone by way of a transdermal patch. In that multiple dose Phase I study, the TPM®/Oxymorphone patch delivered therapeutic oxymorphone plasma concentrations.

In 2014, Phosphagenics’ first pharmaceutical product, a TPM®/Diclofenac gel, was launched by strategic partner Novartis in the Indian market under the brand name Voveran® TPM Gel (Themis Medicare also launched other TPM®/Diclofenac gel products in India under the brand name Instanac® TPM Gel). A further Phase I PK study for the TPM®/Oxymorphone patch confirmed the previous therapeutic oxymorphone concentrations, this time in an additional 15 subjects

Today, Phosphagenics maintains its Australian roots with headquarters in Melbourne, but it is transitioning from a research incubator to a fully commercial operation. Phosphagenics has launched multiple already across the pharmaceutical, consumer care and animal health sectors with products containing TPM® available world-wide.